

ORIGINAL ARTICLE

Evaluation of Exhausted Regulatory T Cells in Preeclampsia

Nahid Daraei¹, Mehri Ghafourian^{1,2*}, Ata Ghadiri¹, Afshin Amari^{1,3}, Mahin Najafian^{2,4}, Saber Rokhafrooz¹

¹Department of Immunology, School of Medicine, ²Fertility, Infertility and Perinatology Research Center, ³Cellular and Molecular Research Center, ⁴Department of Obstetrics and Gynecology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

ABSTRACT

Background: The development of a maternal immune response to fetal antigens and deficiency in regulatory T-cells (Tregs) may lead to preeclampsia. A plausible explanation for the reduced Treg cell function in women with preeclampsia is the presence of exhausted Treg cells which express CD279 or programmed cell death receptor-1 (PD-1), a negative regulatory molecule associated with limited proliferative capacity and reduced immune suppression. **Objective:** To assess the number of Treg CD4⁺ CD25^{high} and exhausted Treg CD4⁺ CD25^{high} CD279⁺ cells in women with preeclampsia (PE group) and healthy pregnant women (HP group) during the third trimester of pregnancy. **Methods:** Three-color flow cytometry was used to determine the proportion of Treg and exhausted Treg cells in 40 women in the PE group and 37 women in the HP group. Participants' blood samples were placed in EDTA blood collection tubes. Peripheral mononuclear cells were separated from the samples and stained with fluoro-chrome-conjugated antibodies against human CD4, CD25 and CD279 markers, and subsequently analyzed by flow cytometry. **Results:** The PE group had fewer Tregs compared to the HP group (p=0.011). There was a significant increase in the percentage of exhausted PD-1⁺(CD279) Tregs (p=0.035) in the PE group comparisons with the HP group. **Conclusion:** The increased number of PD-1 (CD279) molecules on the Treg cells may play a role in preeclampsia, hence it recommendation as a therapeutic target for the disease.

Received: 2018-08-21, Revised: 2018-12-24, Accepted: 2019-05-25.

Citation: Daraei N, Ghafourian M, Ghadiri A, Amari A, Najafian M, Rokhafrooz S. Evaluation of Exhausted Regulatory T Cells in Preeclampsia. *Iran J Immunol.* 2019; 16(2):163-169. doi: 10.22034/iji.2019.80259.

Keywords: Exhausted Regulatory T Cells, Flow cytometry, PD-1, Preeclampsia

*Corresponding author: Dr. Mehri Ghafourian, Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, e-mail: ghafourianbm@gmail.com

INTRODUCTION

One of the severe complications in human pregnancy is preeclampsia (PE) which occurs in the third trimester after 20 weeks of pregnancy (1). Preeclampsia and eclampsia, with no known definitive causes, are the most common reasons for maternal and fetal mortality in 2%-10% of all pregnancies worldwide (2). Moreover, PE has a complex pathophysiology and is the consequence of abnormal placenta formation (3). Regulatory T-cells (Tregs) are a subpopulation of CD4⁺ T-cells detected by the presence of CD4⁺ and CD25^{high} markers on their surfaces. These T-cells have a role in the maintenance of immune system homeostasis and development of tolerance to self-antigens (4). Tregs are involved in the regulation and function of B, T, natural killer (NK), NKT, and antigen presenting cells (4-6). Tregs perform their regulatory function through cell-to-cell contact and with soluble mediators such as CTLA-4, IL-10, TGFβ, and IL-35 (7,8). Exhausted and nonfunctional Treg phenotypes have been reported in infectious and chronic diseases (9). Exhausted Tregs express CD279 [programmed cell death-1 (PD-1)] – a negative regulatory molecule and programmed cell death factor. Treg exhaustion is associated with a gradual loss of proliferation and effector cytokine production (10), along with the co-expression of the inhibitory receptors T-cell immunoglobulin, mucin-domain containing-3 (Tim-3), and lymphocyte activation gene-3 (LAG-3) (11). CD274 or programmed cell death ligand-1 (PDL-1) is a ligand for CD279 on Tregs. Both PD-1 and its ligand are receptors involved in T-cell exhaustion (12). Tregs play an essential role in immune response regulation and tolerance against the fetus (13). During a normal pregnancy, Tregs increase in the blood and maternal decidua (14). The reduced number of Tregs may worsen systemic inflammation in patients with PE, and the prevalence of these cells is lower in the peripheral blood of women with PE compared to HP. Studies on women with PE have shown a reduced Treg population in the peripheral blood and uterine decidua (15,16). Certain studies, on the other hand, have observed similar numbers of Tregs in both patients and controls (2,17). Alterations in Tregs are possibly able to contribute to the development of PE. In this study, we sought to clarify the role of exhausted Tregs in PE and HP women in their third trimester of pregnancy. Further conducted were flow cytometry analyses, investigating the number of Treg CD4⁺ CD25^{high} and exhausted Treg CD4⁺ CD25^{high} CD279⁺ cells in both PE and HP groups.

MATERIALS AND METHODS

Sample Collection. In this case-control study, we enrolled 40 women with PE and 37 healthy pregnant women in their trimester of pregnancy (HP). Both cases and controls were between 18-35 years old and matched for age. The Ethics Committee of Ahvaz University of Medical Sciences (AJUMS) approved this study (IR.AJUMS.REC.1395.1), and all participants provided written informed consent for study participation. Inclusion criteria for PE group were systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, and proteinuria of 300 mg per 24 hours or 30 mg/dl in 2 random urine samples during the third trimester of pregnancy. Excluded subjects were those with chronic kidney disease, history of high blood pressure before the 20th week of pregnancy and prior to pregnancy, bleeding during pregnancy, diabetes mellitus, and autoimmune diseases before pregnancy. The HP (control) group had no history of any chronic kidney diseases, high blood pressure, bleeding, or autoimmune and infectious diseases prior to

pregnancy. Both groups, during the third trimester, provided 3-5 mL samples of blood, then placed in EDTA blood collection tubes (18) and sent to Imam Khomeini Hospital and Razi Hospital, affiliated with AJUMS.

Flow cytometry. Peripheral blood mononuclear cells were isolated by standard density gradient centrifugation for 25 minutes at 400 g and 22°C (Ficoll Paque, BaharAfshan, Iran). The cells were then washed twice with phosphate buffered saline (PBS). White blood cells were stained for 30 minutes at room temperature in the dark with monoclonal antibodies against CD4, CD25, and CD279 markers and their respective Isotype controls (eBioscience, USA). After washing with PBS, the cells were analyzed on a BD FACSCalibur flow cytometer (BD Biosciences, USA), where 100,000 cells were recorded per sample. The data were processed by FlowJo_V10 software, and further examined were CD4⁺ CD25^{high} (19) and exhausted CD4⁺ CD25^{high} CD279⁺ Treg cells.

Statistical Analysis. The Kolmogorov-Smirnov and independent *t*-tests were used to determine the normality of the data and data comparison for both groups, respectively. *p*-value <0.05 were considered significant. GraphPad Prism software (version 6, USA) was used for calculations. Data are presented as mean ± SEM.

RESULTS

Table 1 lists the clinical characteristics of both groups. Tregs were defined as cells with CD4⁺ CD25^{high} markers and exhausted Tregs were considered as those containing CD4⁺ CD25^{high} CD279⁺ markers.

Table 1. Clinical characteristics of study participants.

Characteristics	Healthy pregnant women (n=37)	Preeclamptic women (n=40)	p-value
	Mean ± SEM	Mean ± SEM	
Age (years)	26.5 ± 0.821	28.5 ± 0.925	0.226
Gestational age (weeks)	34 ± 0.322	32 ± 0.534	0.075
Systolic blood pressure (mmHg)	117.5 ± 1.212	160 ± 3.325	0.022*
Diastolic blood pressure (mmHg)	70 ± 1.341	90 ± 3.021	0.031*
Proteinuria	–	≥1+	0.045*

Blood pressure ≥140 mm Hg systolic or ≥90 mm Hg diastolic and proteinuria +1 or higher in the beginning of the twentieth week of pregnancy and the following weeks are diagnostic criteria for preeclampsia.

Figure 1 shows the gating strategy for Tregs and exhausted Tregs and the percentages of Tregs and exhausted Tregs. The results showed a significant decrease in the percentage of CD4⁺ CD25^{high} Tregs in the PE group compared to the HP group (*p*=0.011; Table 2). The comparison of exhausted CD4⁺ CD25^{high} CD279⁺ Tregs between the two groups showed significantly increased numbers of exhausted Tregs (CD279⁺) in the PE group (*p*=0.035; Table 2).




Figure 1. Gating strategies and repertoire of Treg and exhausted Treg cells in peripheral blood of the patient and control groups. (A) Representative flow cytometry analyses of peripheral blood Tregs and exhausted Tregs stained with mAbs to CD4, CD25, and CD279 in healthy pregnant women (HP). **(B)** Representative flow cytometry analyses of peripheral blood Tregs and exhausted Tregs stained with mAbs to CD4, CD25, and CD279 in preeclamptic women (PE). **(C)** The percentage of Treg cells significantly decreased in the PE group compared to the HP group. **(D)** The percentage of exhausted Tregs significantly increased in the PE group compared to the HP group.

Table 2. Prevalence of the cell subsets in women with healthy pregnant (HP) and preeclampsia (PE).

Subset	Marker	HP (n=37), Mean ± SEM	PE (n=40), Mean ± SEM	p-value
Tregs	CD4 ⁺ CD25 ^{high}	1.99 ± 0.156	1.51 ± 0.106	0.011*
Exhausted Tregs	CD4 ⁺ CD25 ^{high} CD279 ⁺	1.84 ± 0.163	2.48 ± 0.366	0.035*

DISCUSSION

In this study, the number of Tregs and exhausted Tregs was evaluated in women with PE versus HP women. There was a reduction in the ratio of CD4⁺ CD25^{high} Tregs in the PE group compared to the HP group. Although numerous studies have reported lower number of Tregs in women with PE compared to HP,(15,20,21) certain studies have observed

similar numbers of Tregs between the patient and control groups (2,17). Despite years of research, the etiology of PE remains unknown. Researchers propose that dysregulated systemic and placental immunity conduce to impaired angiogenesis and the onset of preeclampsia (22). Tregs impose a suppressive effect through cell-to-cell contact and cytokine production (23). Interleukin-10 (IL-10), a key immunosuppressive cytokine produced by Tregs, increases during early pregnancy and remains elevated until the onset of labor (24). IL-10 and its receptor (IL-10R) are expressed on placental trophoblasts, decidual stromal cells, macrophages, and uterine NK cells, which are located at the maternal-fetal interface in both mice and humans (25). Studies show increased percentages of Tregs during normal pregnancy (13,14), indicating that the reduced numbers of Tregs in the peripheral blood of women with PE may be the reason for the decreased fetal tolerance. In the present study, a significant decrease was seen in CD4⁺ CD25^{high} Tregs in the PE group compared to the HP group (19,26-29). The PD-1/PDL-1 pathway is one of the important maintainers of immune homeostasis in the development of Tregs. This pathway inhibits the development of effector T-cells such as Th17. The interaction between PD-1 (CD279) and the CD274 ligand (PD-L1) plays a crucial role in immune response regulation, and is responsible for peripheral tolerance (30). Changes in the PD-1/PD-L1 pathway may be a function of an imbalanced Treg/Th17 ratio during pregnancy (31). Tian *et al.* studied the imbalanced Treg/Th17 cell ratio and the changes in PD-1 and PD-L1 expressions of Treg and Th17 cells in PE women. They observed an inverse correlation between the percentage of Treg and Th17 cells in the control group versus the PE group. In their study, there occurred a significant reduction in the percentage of Tregs in the PE group and an increase in the percentage of Th17 cells. Since PD-1/PD-L1 pathway is essential for the development and function of immune cells, Tian *et al.* have suggested that the reduced number of Tregs in patients with PE might be associated with changes in the expression or function of the PD-1/PD-L1 axis. Their data showed that the percentage of PD1⁺ Tregs in patients with PE was higher compared with the control group, while PD-L1⁺ Tregs did not differ between the two groups. Further seen was a correlation between the expression of PD-1/PD-L1 and the ratio of Treg/Th17 in women with PE compared to HP women. In addition, they noted that these regulatory effects were mediated by the inhibition of PI3K/AKT/mTOR signaling and PTEN expression (32). Our findings on PD1⁺ (CD279⁺) Treg supported the results reported by Tian *et al.*, in which CD4⁺ CD25^{high} CD279⁺ Treg cells increased in the PE group compared to the HP group, and CD4⁺ CD25^{high} Tregs were lower in the PE group. PD-1 expression could be considered as a marker of exhausted T-cells (33). PD-L1 binding to PD-1 has been shown to suppress NFκB factor by inhibiting PI3K activity and downstream activation of the AKT/mTOR pathway (34). The PD-1/PD-L1 pathway might be a therapeutic strategy for autoimmune diseases and PD-1 binding with PD-L1 conduces to the maintenance of pregnancy by adjusting the Treg/Th17 ratio (31). Zhang *et al.* compared PD-1⁺ Tregs between PE and HP women, where the former had a reduced percentage of Tregs and increased percentage of Th17 cells. Moreover, there was a higher PD-1 expression in Tregs and a reduced PD-1 expression regarding Th17 cells in the PE group (35). Our results are in line with the findings of these studies. FoxP3, as a marker for Tregs, was not employed in the present research, hence a limitation. However, a number of studies have only used CD4 and CD25 markers for these cells (19,26-29). We only investigated peripheral blood from the PE and HP groups, which was another study limitation. Future studies should investigate the expression of exhausted Tregs on uterine decidua cells, and assess their activity and signaling. In conclusion, we observed that the

number of Tregs identified by the CD4⁺ CD25^{high} marker decreased in the PE group, but the exhausted Treg cells identified by the CD4⁺ CD25^{high} CD279⁺ marker increased in the PE group. Our data demonstrated that the presence of PD-1 (CD279) on the surface of Tregs, as an apoptosis factor, can be a reason for the reduced number and function of Tregs. This study could be a basis for the designation of suitable therapeutic options for preeclampsia. The increased PD-1 (CD279⁺) observed on Tregs might be involved in the pathogenesis of PE, hence the fact that we recommend that it be used as a therapeutic target for this disorder.

ACKNOWLEDGEMENTS

We would like to express our gratitude to the participating mothers who collaborated with samples for study analysis, and special thanks to the Deputy of Research Affairs of Ahvaz Jundishapur University of Medical Sciences for financial support. This study is extracted from the MSc thesis of Nahid Daraei (Grant No. FIRC-9418).

REFERENCES

1. Molvarec A, Szarka A, Walentin S, Beko G, Karadi I, Prohaszka Z, et al. Serum heat shock protein 70 levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in women with preeclampsia. *Clin Chim Acta*. 2011; 412:1957-62.
2. Boij R, Mjosberg J, Svensson-Arvelund J, Hjorth M, Berg G, Matthiesen L, et al. Regulatory T cell Subpopulations in Severe or Early-onset Preeclampsia. *Am J Reprod Immunol*. 2015; 74:368-78.
3. Fisher SJ. Why is placentation abnormal in preeclampsia? *Am J Obstet Gynecol*. 2015; 213:S115-S22.
4. Lee JY, Lee M, Lee SK. Role of endometrial immune cells in implantation. *Clin Experim Reprod Med*. 2011; 38:119-25.
5. Baecher-Allan C, Wolf E, Hafler DA. Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4⁺ CD25⁺ T cells. *Clin Immunol*. 2005; 115:10-8.
6. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, et al. CD4⁺ CD25⁺ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. *J Exp Med*. 2005; 202:1075-85.
7. Saito S, Sasaki Y, Sakai M. CD4(+)CD25 high regulatory T cells in human pregnancy. *J Reprod Immunol*. 2005; 65:111-20.
8. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. *Nat Rev Immunol*. 2008; 8:523-32.
9. Penaloza-MacMaster P, Kamphorst AO, Wieland A, Araki K, Iyer SS, West EE, et al. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. *J Exp Med*. 2014; 211:1905-18.
10. Wherry EJ. T cell exhaustion. *Nat Immunol*. 2011; 12:492-9.
11. Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, Araki K, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. *Proc Natl Acad Sci USA*. 2010; 107:14733-8.
12. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature*. 2006; 439:682-7.
13. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal human pregnancy is associated with an elevation in the immune suppressive CD25⁺ CD4⁺ regulatory T-cell subset. *Immunology*. 2004; 112:38-43.
14. Guerin LR, Prins JR, Robertson SA. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment?. *Hum Reprod Update*. 2009; 15:517-35.

15. Darmochwal-Kolarz D, Kludka-Sternik M, Tabarkiewicz J, Kolarz B, Rolinski J, Leszczynska-Gorzela B, et al. The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia. *J Reprod Immunol*. 2012; 93:75-81.
16. Sasaki Y, Darmochwal-Kolarz D, Suzuki D, Sakai M, Ito M, Shima T, et al. Proportion of peripheral blood and decidual CD4(+) CD25(bright) regulatory T cells in pre-eclampsia. *Clin Exp Immunol*. 2007; 149:139-45.
17. Paeschke S, Chen F, Horn N, Fotopoulou C, Zambon-Bertoja A, Sollwedel A, et al. Pre-eclampsia is not associated with changes in the levels of regulatory T cells in peripheral blood. *Am J Reprod Immunol*. 2005; 54:384-9.
18. Mjosberg J, Svensson J, Johansson E, Hellstrom L, Casas R, Jenmalm MC, et al. Systemic reduction of functionally suppressive CD4dim CD25 high FoxP3⁺ Tregs in human second trimester pregnancy is induced by progesterone and 17beta-estradiol. *J Immunol*. 2009; 183:759-69.
19. Niu Q, Huang ZC, Cai B, Wang LL, Feng WH. Analysis of frequency of peripheral blood CD4+; CD25(high);Tregs and CD4+; CD25(low);T cells and expression of PD-1 in SLE and RA patients. *Chin J cell Mol Immunol*. 2011; 27:23-5.
20. Darmochwal-Kolarz D, Saito S, Tabarkiewicz J, Kolarz B, Rolinski J, Leszczynska-Gorzela B, et al. Apoptosis signaling is altered in CD4(+)CD25(+)FoxP3(+) T regulatory lymphocytes in pre-eclampsia. *Int J Mol Sci*. 2012; 13:6548-60.
21. Toldi G, Svec P, Vasarhelyi B, Meszaros G, Rigo J, Tulassay T, et al. Decreased number of FoxP3⁺ regulatory T cells in preeclampsia. *Acta Obstet Gynecol Scand*. 2008; 87:1229-33.
22. Kanasaki K, Kalluri R. The biology of preeclampsia. *Kidney Int*. 2009; 76:831-7.
23. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. *Nat Immunol*. 2001; 2:816-22.
24. Hanna N, Hanna I, Hleb M, Wagner E, Dougherty J, Balkundi D, et al. Gestational age-dependent expression of IL-10 and its receptor in human placental tissues and isolated cytotrophoblasts. *J Immunol*. 2000; 164:5721-8.
25. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol*. 2001; 19:683-765.
26. Gregg R, Smith CM, Clark FJ, Dunnion D, Khan N, Chakraverty R, et al. The number of human peripheral blood CD4⁺ CD25^{high} regulatory T cells increases with age. *Clin Exp Immunol*. 2005; 140:540-6.
27. Hamza E, Akdis CA, Wagner B, Steinbach F, Marti E. In vitro induction of functional allergen-specific CD4⁺ CD25^{high} Treg cells in horses affected with insect bite hypersensitivity. *Clin Exp Allergy*. 2013; 43:889-901.
28. Nan XP, Zhang Y, Yu HT, Sun RL, Peng MJ, Li Y, et al. Inhibition of viral replication downregulates CD4(+) CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B. *Viral Immunol*. 2012; 25:21-8.
29. Park HJ, Park JS, Jeong YH, Son J, Ban YH, Lee BH, et al. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8⁺ T cell immune response via the interaction with PD-L1 expressed on CD8⁺ T cells. *J Immunol*. 2015; 194:5801-11.
30. Giancchetti E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. *Autoimmun Rev*. 2013; 12:1091-100.
31. Tripathi S, Guleria I. Role of PD1/PDL1 pathway, and TH17 and treg cells in maternal tolerance to the fetus. *Biomedical J*. 2015; 38:25-31.
32. Tian M, Zhang Y, Liu Z, Sun G, Mor G, Liao A. The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats. *Sci Rep*. 2016; 6:27683.
33. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. *Nat Immunol*. 2007; 8:239-45.
34. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. *Mol Cell Biol*. 2005; 25:9543-53.
35. Zhang Y-H, Hu X-H, Liao A-H. PD-1 pathway regulates Treg/Th17 imbalance by interfering cell proliferation in pre-eclampsia. *J Reprod Immunol*. 2016; 115:82.